专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP2064556B1 METHOD TO IDENTIFY AND TREAT SUBJECTS RESISTANT TO ACETYL SALICYLIC ACID 有权
标题翻译：方法识别和治疗患者抗乙酰水杨酸
公开(公告)号：EP2064556B1
公开(公告)日：2017-05-10
申请号：EP07827651.6
申请日：2007-08-30
申请人： Pulcinelli, Fabio Maria , Frati, Luigi
发明人： PULCINELLI, Fabio Maria , FRATI, Luigi , MATTIELLO, Teresa
IPC分类号： G01N33/68 , G01N33/86 , G01N33/94 , C12Q1/68 , A61K31/616
CPC分类号： A61K31/616 , C12Q1/6883 , C12Q2600/106 , C12Q2600/158 , G01N33/6893 , G01N33/9486 , G01N2333/705 , G01N2800/222 , G01N2800/224 , G01N2800/226 , G01N2800/2871 , G01N2800/44
摘要： The invention relates to the use of acetyl salicylic acid (ASA) in combination with MRP4 channel inhibitors for the treatment of all diseases related to so-called ASA resistance. Particularly preferred among the MRP4 channel inhibitors is dipyridamole. The invention also relates to an in-vitro diagnostic method for identifying ASA-resistant patients and to the associated kit for implementing the diagnostic method.
摘要翻译：本发明涉及组合使用乙酰水杨酸（ASA）与相关的所谓的ASA电阻所有疾病的治疗MRP 4通道抑制剂。 MRP的4通道抑制剂中特别优选的是双嘧达莫。因此本发明涉及一种体外诊断方法，用于鉴定ASA-耐药患者和用于实施该诊断方法的试剂盒相关联。

2. 发明授权

EP2821499B1 METHOD FOR THE RAPID DETERMINATION OF SUSCEPTIBILITY OR RESISTANCE OF BACTERIA TO ANTIBIOTICS 有权
标题翻译：方法对抗生素敏快速测定或抵抗细菌的
公开(公告)号：EP2821499B1
公开(公告)日：2017-02-15
申请号：EP13382271.8
申请日：2013-07-04
申请人： ABM Technologies, LLC
发明人： Fernández García, José Luis , Gosálvez Berenguer, Jaime , Santiso Brandariz, Rebeca , Tamayo Novás, María , Bou Arévalo, Germán
IPC分类号： C12Q1/04 , C12Q1/18
CPC分类号： C12Q1/18 , C12Q1/04 , G01N2800/44
摘要： A method of rapidly evaluating the susceptibility of a strain of bacteria to a cell wall synthesis inhibiting antibiotic based on an assessment of cell enlargement in response to doses of the cell wall synthesis inhibiting antibiotic which are correlated to breakpoints of bacterial susceptibility.

3. 发明授权

EP2687608B1 Methods for the identification, assessment, and treatment of patients with cancer therapy 有权
标题翻译：程序的癌症患者治疗的识别，评估和治疗
公开(公告)号：EP2687608B1
公开(公告)日：2017-02-08
申请号：EP13181515.1
申请日：2006-06-08
申请人： MILLENNIUM PHARMACEUTICALS, INC.
发明人： Bryant, Barbara , Damokosh, Andrew , Mulligan, George
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , A61K31/69 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , G01N33/57407 , G01N33/57415 , G01N33/57419 , G01N33/57423 , G01N33/57426 , G01N33/57434 , G01N33/57438 , G01N33/57449 , G01N2800/44 , G06F19/20 , G06F19/24 , G06Q20/40 , G06Q50/22 , Y02A90/22 , Y02A90/26
摘要： The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
摘要翻译：本发明涉及预测标志物的鉴定也可以用于确定性地矿是否患有癌症的患者是临床响应或不响应于治疗前的治疗方案。特别地，本发明涉及使用某些个体和/或预测性标记物的组合的，worin预测标志物的表达与反应性或无反应性的治疗方案相关。因此，通过检查各个预测标志物和/或预测性标记物，其包括标记组的表达水平，所以能够确定矿无论药剂的治疗剂，或它们的组合，将最有可能减少在临床肿瘤的生长速率设置。

4. 发明授权

EP2666015B1 USE OF STATHMIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES 有权
标题翻译： stathmin的作为生物标志物用于的响应与FURAZANOBENZIMIDAZOLEN药品的使用
公开(公告)号：EP2666015B1
公开(公告)日：2016-12-28
申请号：EP12700827.4
申请日：2012-01-19
申请人： Basilea Pharmaceutica AG
发明人： LANE, Heidi Alexandra , BACHMANN, Felix
IPC分类号： G01N33/50 , A61K31/00
CPC分类号： G01N33/6893 , A61K31/4184 , A61K31/4245 , C07D413/04 , C07D413/14 , G01N33/5011 , G01N33/5026 , G01N2800/44 , G01N2800/52

5. 发明授权

EP2500435B1 Identification of antibiotic resistance in micro organisms 有权
标题翻译：在微生物中抗生素抗性的检测
公开(公告)号：EP2500435B1
公开(公告)日：2016-09-21
申请号：EP11158836.4
申请日：2011-03-18
申请人： miacom Diagnostics GmbH
发明人： Freiherr von Stein, Walter , Stange, Mirko
IPC分类号： C12Q1/18 , G01N33/569 , C12Q1/68 , C12N15/82
CPC分类号： C12Q1/689 , C07K16/40 , C12Q2600/106 , C12Q2600/136 , G01N33/569 , G01N2333/31 , G01N2800/44

6. 发明授权

EP2580598B1 MASS SPECTROMETRIC MEASUREMENT OF ß-LACTAMASE RESISTANCES 有权
标题翻译：质谱法测定β-内酰胺酶抗性
公开(公告)号：EP2580598B1
公开(公告)日：2014-08-06
申请号：EP11728209.5
申请日：2011-06-10
申请人： Bruker Daltonik GmbH
发明人： KOSTRZEWA, Markus , MICHELMANN, Karsten , SPARBIER, Katrin
IPC分类号： C12Q1/18 , G01N33/68 , C12Q1/34
CPC分类号： C12Q1/18 , C12Q1/34 , G01N33/6851 , G01N2333/986 , G01N2800/26 , G01N2800/44

7. 发明公开

EP2673373A2 ANTIBODIES THAT SPECIFICALLY BIND STAPHYLOCOCCUS AUREUS ALPHA TOXIN AND METHODS OF USE 有权
标题翻译：抗体特异性结合金黄色葡萄球菌α毒素及其使用方法
公开(公告)号：EP2673373A2
公开(公告)日：2013-12-18
申请号：EP12745207.6
申请日：2012-02-07
申请人： MedImmune, LLC
发明人： SELLMAN, Bret , TKACZYK, Christine , HUA, Lei , CHOWDHURY, Partha , VARKEY, Reena , DAMSCHRODER, Melissa , PENG, Li , OGANESYAN, Vaheh , HILLIARD, Jamese, Johnson
IPC分类号： C12P21/08 , C07K16/00 , A61K39/40 , A61K39/085
CPC分类号： C07K16/1271 , A61K38/14 , A61K39/40 , A61K45/06 , A61K2039/505 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/76 , C07K2317/90 , C07K2317/92 , G01N33/56938 , G01N2333/31 , G01N2800/20 , G01N2800/44 , G01N2800/709 , A61K2300/00
摘要： Herein provided are compositions, methods of manufacture and methods of use pertaining to anti-alpha toxin antibodies and fragments.

8. 发明公开

EP2598890A2 MIG6 AND THERAPEUTIC EFFICACY 审中-公开
标题翻译： MIG6，它的治疗效果
公开(公告)号：EP2598890A2
公开(公告)日：2013-06-05
申请号：EP11815062.2
申请日：2011-07-26
申请人： The Johns Hopkins University
发明人： SIDRANSKY, David , CHANG, Xiaofei
IPC分类号： G01N33/68 , C12Q1/68 , G01N33/574
CPC分类号： C12Q1/6886 , C07K16/18 , C12Q1/485 , C12Q2600/106 , G01N33/57407 , G01N33/6872 , G01N2333/91205 , G01N2800/44
摘要： We identify markers capable of guiding the decision to incorporate epidermal growth factor receptor (EGFR) inhibitors, in particular EGFR tyrosine kinase inhibitors (TKIs), into chemotherapeutic regimens. Mitogen-inducible gene 6 (Mig6), a negative regulator of EGFR, is selectively upregulated during the development of resistance to the EGFR tyrosine kinase inhibitor (TKI) erlotinib, resulting in decreased EGFR phosphorylation. The ratio of Mig6/EGFR expression highly correlates with erlotinib sensitivity. A low Mig6/EGFR ratio correlates with a high response rate to gefitinib and a marked increase in progression-free survival for patients. The ratio of Mig6 to EGFR is a major predictor of biologic and clinical responses to EGFR inhibitors.

9. 发明公开

EP2596355A2 METHODS FOR ISOLATING AND USING A SUBSET OF CD8 T-CELLS THAT ARE RESISTANT TO CYCLOSPORIN 审中-公开
标题翻译：方法分离和用来对付耐环孢素CD8 + T细胞数量的部分
公开(公告)号：EP2596355A2
公开(公告)日：2013-05-29
申请号：EP11810513.9
申请日：2011-07-25
申请人： Johnson, Raymond M.
发明人： Johnson, Raymond M.
IPC分类号： G01N33/53 , C12N5/0783 , C12Q1/24
CPC分类号： C12N5/0636 , C12N5/0637 , C12N2501/04 , C12N2501/06 , G01N33/505 , G01N2333/70517 , G01N2800/44
摘要： Utilizing a novel T cell culture system based on allogeneic epithelial antigen presenting cells (semi-professional APC), a cyclosporin-resistant CD8 T cell clone with minimal cytolytic capability was isolated. Derivation of the novel alloantigen-specific CD8 T cell clones involved previous priming with an allogeneic skin graft, implying expansion of this T cell subset during transplant rejection. Characterization and comparison of the cyclosporin and rapamycin-resistant CD 8 T cell clone with typical cyclosporin-sensitive CD 8 T cells suggests that it is a member of a CD8 T cell subset with a unique cell surface phenotype and novel TCR activation pathways, and that these unique CD8 T cell clones reflect the immunobiology of chronic rejection within the non-hematopoetic microenvironments of solid organs and vascular walls. These cells express the aryl-hydrocarbon receptor. T-cells of this type are referred to herein as CD8bm12-1 T-cells.

10. 发明公开

EP2554993A1 MARKER FOR DIAGNOSING EFFECT OF ANTICANCER AGENT 审中-公开
标题翻译： MARKER ZUR DIAGNOSE DER WIRKUNG EINES ANTIKREBSMITTELS
公开(公告)号：EP2554993A1
公开(公告)日：2013-02-06
申请号：EP11765360.0
申请日：2011-03-18
申请人： Fujirebio Inc.
发明人： ISE, Nobuyuki , NAMBARA, Daisuke , OMI, Kazuya
IPC分类号： G01N33/574 , C07K16/30 , C07K16/40
CPC分类号： C07K16/2863 , C12Q1/485 , G01N33/5011 , G01N33/566 , G01N33/574 , G01N33/57423 , G01N33/57492 , G01N2500/00 , G01N2800/44 , G01N2800/52
摘要： The present invention enables to realize a convenient determination of a therapeutic effect of an anticancer agent on a cancer. Specifically, the present invention provides a diagnostic marker for an effect of an anticancer agent on a cancer, comprising a substance having an affinity for a fragment of an extracellular domain of c-MET; a diagnostic reagent for an effect of an anticancer agent on a cancer, comprising a substance having an affinity for a fragment of an extracellular domain of c-MET and the fragment of the extracellular domain of c-MET; and a method of testing an effect of an anticancer agent on a cancer, comprising (a) measuring a concentration of a fragment of an extracellular domain of c-MET in a biological sample from a subject, and (b) comparing the measured concentration of the fragment of the extracellular domain of c-MET with an indicator which presents a relationship between a concentration of the fragment of the extracellular domain of c-MET and the effect of the anticancer agent on the cancer.
摘要翻译：本发明能够实现抗癌剂对癌症的治疗效果的方便的测定。具体地说，本发明提供了抗癌剂对癌症的作用的诊断标记物，其包含对c-MET细胞外结构域片段具有亲和力的物质; 用于抗癌剂对癌症的作用的诊断试剂，其包含对c-MET细胞外结构域片段和c-MET细胞外结构域片段具有亲和性的物质; 以及测试抗癌剂对癌症的作用的方法，包括（a）测量来自受试者的生物样品中c-MET的细胞外结构域的片段的浓度，和（b）将测量的浓度 c-MET细胞外结构域的片段与c-MET细胞外结构域片段的浓度与抗癌剂对癌症的作用之间的关系表示指示。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式